Response data by treatment arm
| . | Arm A, concurrent R-EPOCH . | Arm B, sequential EPOCH → R . |
|---|---|---|
| Preamendment | ||
| No. treated/evaluable | 17/17 | 18/16 |
| CR or CRu | 14 (82%) | 11 (69%) |
| 95% CI | 57%-96% | 41%-89% |
| CR + PR | 16 (94%) | 13 (82%) |
| Postamendment | ||
| No. treated/evaluable | 34/31 | 37/37 |
| CR or CRu | 21 (68%) | 18 (49%) |
| 95% CI | 49%-83% | 32%-66% |
| CR + PR | 26 (84%) | 28 (76%) |
| All patients* | 51/48 | 55/53 |
| No. treated/evaluable | ||
| CR or CRu | 35 (73%) | 29 (55%) |
| 95% CI | 58%-85% | 41%-68% |
| CR + PR | 42 (88%) | 41 (77%) |
| . | Arm A, concurrent R-EPOCH . | Arm B, sequential EPOCH → R . |
|---|---|---|
| Preamendment | ||
| No. treated/evaluable | 17/17 | 18/16 |
| CR or CRu | 14 (82%) | 11 (69%) |
| 95% CI | 57%-96% | 41%-89% |
| CR + PR | 16 (94%) | 13 (82%) |
| Postamendment | ||
| No. treated/evaluable | 34/31 | 37/37 |
| CR or CRu | 21 (68%) | 18 (49%) |
| 95% CI | 49%-83% | 32%-66% |
| CR + PR | 26 (84%) | 28 (76%) |
| All patients* | 51/48 | 55/53 |
| No. treated/evaluable | ||
| CR or CRu | 35 (73%) | 29 (55%) |
| 95% CI | 58%-85% | 41%-68% |
| CR + PR | 42 (88%) | 41 (77%) |
CRu indicates complete response (unconfirmed).
In an intention-to-treat analysis in all treated patients, the CR rates 69% in the concurrent arm (95% CI, 54%-81%) and 53% in the sequential arm (95% CI, 39%-66%).